LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board
of Directors
London, 1 July 2024- LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly
emerging biotech company preparing to start clinical trials for its first-in-
class allogeneic innate cell therapy, today announces the appointment of Antonin
(Tony) de Fougerolles, PhD as Chairman of its Board.
Tony brings over 25 years of biotech R&D experience in building out drug
pipelines and bringing new-to-world therapeutic modalities to patients. He has
most recently served as CEO of Evox Therapeutics and previously, served as CSO
of Ablynx, where he led the company's non-clinical R&D operations and played a
key role in the approval of the first single domain antibody drug, caplacizumab
and in building out a portfolio of immuno-oncology and immunology products.
Prior to this, Tony held several leadership positions, including founding CSO at
Moderna Therapeutics where he developed and invented much of the foundational
science behind their revolutionary mRNA platform, CSO at Tolerx, Inc and VP of
Research at Alnylam. He currently serves on the boards of etherna and Chimeron
Bio and is also an advisor to MiNA Therapeutics. Tony holds a PhD in Immunology
from Harvard University and a BSc in Microbiology & Immunology from McGill
University.
Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: "On behalf of
LIfT's Board of Directors, I am pleased to welcome Tony to the Company as
Chairman. Tony has extremely relevant experience, having played a key role in
successfully bringing three new drug modalities to the market, extensive
experience in immuno-oncology, and has helped build several multi-billion-dollar
companies from start-up stage. This wealth of experience will prove invaluable
to LIfT as we prepare to move into clinical trials for our allogeneic first-in-
class neutrophil-based immuno-cell therapy and other exciting pipeline
developments."
Antonin (Tony) De Fougerolles, Chairman of the Board commented: "I'm delighted
to join LIfT at such a crucial stage in its journey. The team at LIfT have been
leading the field in characterising and developing an immuno-oncology
therapeutics platform around a newly described subset of neutrophils called
Immuno-Modulatory Alpha Neutrophils (IMANs). These IMANs dramatically outperform
traditional neutrophils in their tumour killing abilities by rapidly
infiltrating tumours and recruiting additional immune cells. As an immunologist,
it is not a surprise that neutrophils like other immune cell types are also
comprised of subsets of cells with different functions. I look forward to using
my varied experience to support Alex and the team to advance LIfT's IMANs
through the clinic towards the market as a new transformational therapy for
solid tumours."
About LIfT BioSciences
LIfT Biosciences is a biotech bringing to market a first-in-class proprietary
immuno-cell therapy that overcomes the limitations of current therapies in solid
tumours by destroying tumours both directly and indirectly. LIfT's
Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment
against the tumour as they recruit the rest of the immune system to destroy the
tumour to give a durable response and lasting immunity. The breakthrough N-LIfT
platform is produced from a patented process using exceptional stem cells (iPSC
or HSC), a proprietary enhancement media and genetic engineering. IMANs are
believed to possess a critical immune component that many cancer patients lack
to get the necessary immune response to achieve remission.
The company is developing a portfolio of CAR IMAN cell therapies and IMAN
combination therapies across oncology and other complementary therapy areas. See
www.liftbiosciences.com (http://www.liftbiosciences.com).
Further information
Investors & Media:
ablyth@LIfTBioSciences.com
(mailto:ablyth@LIfTBioSciences.com)
Alex Blyth liftbiosciences@consilium-comms.com
ICR Consilium
Mary-Jane Elliott,
Namrata Taak, Lindsey
Neville +44 (0)7718 759116
Â